The biologic and pathologic features of B-cell malignancies bearing a translocation t(14;19)(q32;q13) leading to a fusion of IGH and BCL3 are still poorly described. Herein we report the results of a comprehensive cytogenetic, fluorescence in situ hybridization (FISH), molecular and histopathological survey of a large series of B-cell malignancies with t(14;19) or variant translocations. A total of 56 B-cell malignancies with a FISHproven BCL3 involvement were identified with the translocation partners being IGH (n ¼ 51), IGL (n ¼ 2), IGK (n ¼ 2) and a non-IG locus (n ¼ 1). Hierarchical clustering of chromosomal changes associated with the t(14;19) indicated the presence of two different groups of IG/BCL3-positive lymphatic neoplasias. The first group included 26 B-cell malignancies of various histologic subtypes containing a relatively high number of chromosomal changes and mostly mutated IgVH genes. This cluster displayed three cytogenetic branches, one with rearrangements in 7q, another with deletions in 17p and a third one with rearrangements in 1q and deletions in 6q and 13q. The second group included 19 cases, mostly diagnosed as B-cell chronic lymphocytic leukemia (B-CLL), and characterized by few additional chromosomal changes (e.g. trisomy 12) and unmutated IgVH genes. In conclusion, our study indicates that BCL3 translocations are not restricted to B-CLL but present in a heterogeneous group of B-cell malignancies.
Introduction
The t(14;19)(q32;q13) is a recurrent chromosomal change in Bcell malignancies. [1] [2] [3] As a result of this translocation, BCL3 in 19q13, a coactivator of the nuclear factor kappaB (NF-kB) family of transcription factors, 4 is deregulated by its juxtaposition with regulatory elements of the immunoglobulin heavy chain (IGH) locus in 14q32. 5, 6 However, similar to other lymphoma-related IGH translocations such as the t(14;18)(q32;q21), 7 the sole presence of a t(14;19)(q32;q13) translocation is not sufficient to induce tumorigenesis, as shown in a Em-Bcl3 transgenic mouse model. 8 Therefore, the acquisition of additional genetic aberrations is considered to be necessary for malignant transformation.
In contrast to other chromosomal translocations involving IG loci in B-cell lymphomas, for example, t(8;14)(q24;q32) (IGH/ MYC) in Burkitt lymphoma (BL), t(11;14)(q13;q32) (IGH/ CCND1) in mantle cell lymphoma (MCL) or t(14;18)(q32;q21) (IGH/BCL2) in follicular lymphoma (FL), 9 ,10 the clinical and pathological significance of IG/BCL3 fusions is still poorly defined. To date, approximately 40 cases with a t(14;19) (q32;q13) have been reported in the literature, mostly diagnosed as B-cell chronic lymphocytic leukemia (B-CLL)/small lymphocytic lymphoma (SLL) (reviewed in Soma et al. 11 ). However, the B-CLL/SLLs with t(14;19)(q32;q13) are often phenotypically atypical, and sometimes appear in younger patients and have a more aggressive clinical course. A recent report by Huh et al. 12 suggests that t(14;19)-positive leukemias with B-CLL-like features represent a different entity, which was coined t(14;19)-positive small B-CLL leukemia. Non-CLL-type B-cell malignancies with t(14;19)(q32;q13) have been diagnosed as FL, diffuse large B-cell lymphoma (DLBCL), Burkitt-like lymphoma, splenic B-cell lymphoma (SBCL), splenic marginal zone lymphoma (SMZL) and even classical Hodgkin lymphoma (cHL).
BCL3 involvement in t(19q13)-positive cases by molecular methods, including fluorescence in situ hybridization (FISH).
A systematic analysis of well characterized t(14;19)-positive leukemias/lymphomas with BCL3 involvement is required to determine whether these cases might represent a distinct clinicopathological entity. Therefore, we have performed a comprehensive multicenter study of a large series of B-cell malignancies with t(14;19)(q32;q13) or variant translocations using standard cytogenetic analysis, FISH, IgVH mutation analysis and a histopathological review of IG/BCL3-positive cases.
Materials and methods

Tumor samples
B-cell malignancies with cytogenetically detected 19q13 breakpoints were selected from the cytogenetic databases of the laboratories involved in the present study. Conventional G-or R-banding chromosomal analysis was performed according to routine methods in each of the institutions. Cytogenetic suspensions from a total of 80 hematological tumors were included in the study. From those, 56 were B-cell malignancies containing a cytogenetically detected t(14;19)(q32;q13) translocation or variants t(2;19)/t (19;22) . Twenty-one were hematological malignancies (18 B-and three T-cell lymphomas) displaying breakpoints in 19q13 without cytogenetic evidence for involvement of any of the IG loci in 14q, 2p or 22q. Three additional cases in which an IGH/BCL3 fusion was detected by interphase FISH but without informative cytogenetic analysis were also included in the study. Some cases of the present series have been published before in a different context. 2, 12, 15, 20 As cases studied were not part of a consecutively ascertained series, conclusions about incidences cannot be drawn.
Paraffin-embedded material and/or cytospin slides were available from a total of 25 cases with FISH-proven IG/BCL3 fusions. Histopathological analysis of lymph node sections was carried out in 17 B-cell lymphomas from which, in three cases, cytospins for cytological analyses were also available. In eight cases, only a cytological review of bone marrow/peripheral blood cytospins was possible. The histopathological review was performed by a panel of expert hematopathologists from three different institutions (WK and H-HW from Kiel, Germany; FB and PF from Lyon, France; CDW-P from Leuven, Belgium). An evaluation sheet was designed and the tissue material together with patient information gathered at diagnosis (age, gender, diagnosis, morphological data and the immunophenotype generated by immunohistochemistry, flow cytometry or both) was sent sequentially to each of the three institutions. If necessary, additional immunohistochemical analyses were performed in the course of the pathological review according to routine methods. Finally, data were gathered together and a consensus diagnosis based on the panel review was established. This study was performed according to the guidelines of the joint project 'Molekulare Mechanismen bei malignen Lymphomen' for which ethics approval was obtained.
FISH analyses for the detection of BCL3 rearrangements
For the detection of chromosomal rearrangements of the BCL3 locus, a dual-color break-apart probe was designed using BAC clones (centromeric: RP11-21J15; telomeric: pooled CTB-129P6 and CTB-179K24; Figure 1 ). For studying chromosomal breaks in the IG loci, break-apart probes flanking IGH (Vysis/Abbott, Downers Grove, IL, USA), IGL and IGK were applied. 21 Threecolor FISH assays for the detection of IG/BCL3 were designed combining IG break-apart probes (labeled in Spectrum Orange and Spectrum Green) with the three BAC clones for BCL3 labeled in diethyl aminomethyl coumarin (DEAC). The 9p13 break in case 56 with a t(9;19)(p13;q13) was characterized with BAC clones RP11-220I1 and RP11-1P6. The probes for CCND3 and BCL11A have been described previously. 20, 22 FISH analyses were performed on cytogenetic suspensions from 80 leukemias and lymphomas with 19q13 breaks according to previously described protocols. 21 Slides were analyzed using a Zeiss Axioskop-2 fluorescence microscope (Zeiss, Gö ttingen, Germany) equipped with appropriate filter sets (AHF, Tü bingen, Germany) and documented using an ISIS imaging system (MetaSystems, Altlussheim, Germany). The diagnostic cutoff for the newly developed FISH probes was estimated using cytogenetic suspensions from peripheral blood samples of five negative controls, as previously described. 21 
IgVH mutation analysis
In 27 cases, IgVH genes were amplified by nested polymerase chain reaction (PCR) using a mixture of oligonucleotide 5 0 primers specific for each leader sequence of the VH1 to VH6 families and a consensus 3 0 primer complementary to the germline JH region followed by a pair of internal primers to the consensus 5 0 FW1 region and the 3 0 germline JH region. Clonal sequences were determined by sequencing amplicons from at least two independent PCR reactions. Samples were either subcloned or sequenced directly using an ABI310 DNA sequencer. Nucleotide sequences were aligned to the V-BASE sequence directory using Lasergene; DNASTAR (Madison, WI, USA) software. Percentage sequence identity was calculated by counting the number of mutations between the 5 0 end of FR1 and the 3 0 end of FR3. In three additional cases, different previously described protocols were used. 23, 24 Statistical analyses in IG/BCL3-positive cases
The presence or absence of chromosomal aberrations as detected by banding analyses was recorded and only those abnormalities present in more than 5% of the FISH-proven IG/ BCL3-positive cases were entered into the statistical study. Average linkage hierarchical clustering was performed using the Jaccard coefficient for binary variables. 25 IgVH mutation frequency and cytogenetic complexity (defined as the number of chromosomal changes in addition to the IG/BCL3 fusion) in different clusters were compared by the non-parametric MannWhitney U-test. All statistical analyses were performed using the SPSS statistical software (version 13.0 for Windows).
Results
FISH for the detection of BCL3 breakpoints
To confirm the presence of BCL3 breakpoints in the cases with t(14;19)(q32;q13) or variants, FISH using a BCL3 break-apart probe was applied (Figure 1) . A signal split was defined as a distance between the signals derived from the centromeric and telomeric probes of more than three times the estimated signal diameter. Using this criterion, the cutoff of the BCL3 break-apart probe was determined as 0.8% based on negative controls. Fusion of BCL3 to IG loci was proven by using a three-color IG/ BCL3 probe, for which the cutoff for signal patterns indicating the presence of a translocation was virtually zero.
Fifty-two of the 56 hematological malignancies with t(14;19) or variants displayed signal constellations consistent with the presence of a BCL3 breakpoint. These included 48 with a t(14;19), two with a t (19;22) and two with a t(2;19). A BCL3 breakpoint was also detected in three additional cases with an interphase FISH-proven IGH break but without available cytogenetic analysis. The median number of interphase nuclei indicating the presence of a BCL3 breakpoint was 58% (range ¼ 2-92%). An IG/BCL3 juxtaposition was demonstrated by three-color FISH in cases with breaks in BCL3 and any of the IG loci leading to a total of 55 cases with FISH-proven IG/BCL3 fusions.
A screening of 21 lymphoid malignancies with 19q13 breaks lacking 14q32, 22q11 or 2p11-12 involvement was performed to assess for the presence of variant non-IG BCL3 rearrangements. Twenty cases had signal patterns indicating the presence of a non-rearranged BCL3 locus. One case of unspecified aggressive B-cell lymphoma showed 97% of the scored nuclei to have a BCL3 rearrangement. This case contained a t(9;19)(p13;q13) translocation by conventional cytogenetics as well as a BCL6 breakpoint detected by interphase FISH. The 9p13 breakpoint was located 0.2-1.1 Mb centromeric to the PAX5 locus between BACs RP11-220I1 and RP11-1P6, as shown by additional interphase FISH (data not shown). In summary, a total of 56 cases displayed signal patterns indicating the presence of a chromosomal breakpoint in the BCL3 locus ( 9p13/BCL3 F Abbreviations: aB-NHL, aggressive B-cell non-Hodgkin lymphoma not otherwise specified; B-CLL nos: B-cell chronic lymphocytic leukemia not otherwise specified, (atypical): indicates the presence of an atypical morphology and/or immunophenotype; B-CLL/SLL, B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma; B-NHL, B-cell non-Hodgkin lymphoma not otherwise specified; cHL, classical Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphomal; FL, follicular lymphoma; iB-NHL, indolent B-cell non-Hodgkin lymphoma not otherwise specified; MZL, marginal zone lymphoma, ND, not done; SMZL, splenic marginal zone lymphoma; TCBCL, T-cell-rich B-cell lymphoma. Diagnoses in bold letters were reviewed by a panel of expert hematopathologists ( a based on histochemistry.
b Based on cytology). A 't' after the diagnosis indicates that the case had signs of transformation. Cases 1, 2, 4, 11, 27, 44, 45 and 51 have been previously published. 2, 12, 15, 20 c Data from this specific case were not obtained at the onset of the B-CLL but in a sample in transformation to DLBCL. the IGH locus was not identified in two cases that were reported as an add(14)(q32).
Pathological features of patients with IG/BCL3 fusion
The pathology panel review performed on 25 cases with FISHproven BCL3 translocation revealed a broad morphologic spectrum including four B-CLLs, seven marginal zone lymphomas (MZL), three DLBCLs, one IG/BCL2-negative FL grade I, six not-otherwise specified aggressive B-cell lymphomas (one of them with a 9p13/BCL3 fusion) and three not-otherwise specified indolent B-cell lymphomas. The diagnosis in one additional case was borderline between cHL and T-cell rich B-cell lymphoma (TCBCL). A high background of reactive T-cells and histiocytes was frequently found in the DLBCLs. Furthermore, several of the indolent lymphomas displayed signs of accelerated disease or transformation with increased number of blasts. Only 3/25 cases resembled B-CLL morphologically.
Cytological examination was consistent with B-CLL in 4/11 cases. In 6/11 cases, the cytological diagnosis was MZL of which four were diagnosed as splenic MZL. Three B-CLL and four MZL displayed cytological features of disease progression with increased polymorphism and occurrence of larger cells. All lymphomas with BCL3 translocations included in the pathological review were CD20-positive B-cell lymphomas. Coexpression of CD5 or CD23 was detectable only in 7/13 and 6/16 cases, respectively, and was often present only in a minority of cells (data not shown). CD10 coexpression was not detectable in any of the cases examined (0/11). A description of the diagnoses and immunophenotypes of reviewed and unreviewed cases with a BCL3 translocation is shown in Table 1 .
The majority of the cases diagnosed as B-CLL could not be reviewed, and therefore, although these cases were classified as B-CLL, the diagnosis has not been centrally confirmed. B-CLLs lacking pathological review and sufficient immunophenotypic data are classified in Table 1 as B-CLL not otherwise specified (nos). However, several lines of evidence support the diagnosis of B-CLL in cases that were not reviewed: (a) they were initially diagnosed as B-CLL (or atypical B-CLL) by an expert hematologist; (b) the fact that no material was available for pathological review indirectly shows that smears were used at the time of diagnosis, as is typical for leukemic cases, and these are not subjected to long-term storage; (c) in contrast to classical B-CLLs, B-CLL-like t(14;19)-positive leukemias are frequently CD23 negative 12 and in line with this finding, 5/8 of the B-CLLs in our series with available CD23 status were also CD23 negative; (d) t(14;19)-positive B-CLLs reported in the literature usually show relatively simple karyotypes with a high frequency of trisomy 12 and most of the cases classified as B-CLLs in our study also show these cytogenetic features. Interestingly, trisomy 12 has also been reported to be associated with atypical B-CLLs. 26 The finding that several B-CLLs in this study were morphologically and/or immunophenotypically described as 'atypical' might indicate that they represent a peculiar subgroup of B-cell lymphatic disease, as recently proposed. 12 Thus, although the term 'B-CLL' is used throughout this article to classify IG/BCL3-positive atypical B-CLLs, they might represent a different pathological entity from classical B-CLL.
IgVH mutation analysis of B-cell disorders with IG/BCL3 fusion
IgVH mutation analysis was performed in 30/56 B-cell lymphomas with FISH-proven BCL3 translocation. The IgVH mutation status could be determined in 26 B-cell malignancies (14 B-CLL, six MZL, three indolent B-NHL NOS and one each DLBCL, SMZL and B-cell lymphoma NOS), 12 of them included in the pathological review. IgVH mutation analysis was not evaluable in four cases. In 21 cases (81%), IgVH sequences showed 98-100% sequence identity to germline VH-genes and, thus, by definition lacked somatic mutations. 27 However, five of these cases showed more than 98% sequence identity but lower than 99.5%, which might suggest the presence of a moderate IgVH mutation frequency, as recently pointed by the European Research Initiative on CLL (ERIC) group. 28, 29 In the remaining five cases (19%), the sequence identity to germline IgVH was below 98% and ranged from 92.6 to 97.8% indicating somatic hypermutation. Cases clearly lacking IgVH mutations were predominantly diagnosed as B-CLLs (13/16), whereas those with somatic hypermutation (including those with 98-99.5% sequence identity) were mostly diagnosed as MZL (6/10) or other B-cell lymphomas different from B-CLLs (3/10).
Interestingly, three Igk-positive B-CLLs (cases 4, 11 and 24) contained VDJ rearrangements using the V4-39/D6-13/JH5a segments leading to a total of 20% (3/15) B-CLLs with highly similar B-cell antigen receptors.
Cluster analysis of chromosomal changes associated with the IG/BCL3 fusion
From the 55 B-cell lymphomas with FISH-proven IG/BCL3 fusion, a total of 47 met the criteria to enter the statistical cluster analyses, that is karyotype available and presence of cytogenetically detected secondary changes associated with the t(14;19) or variants. Twelve cytogenetic variables ( Figure 2 ) were shown to be present in more than 5% of the cases with IG/BCL3 fusion and were included in the statistical analysis. The results indicate the presence of two main clusters, which included 26 and 19 cases, respectively. Two cases did not cluster with either of these groups. Cluster 1 was divided into three different subgroups (A, B and C). Cluster 1A (seven cases) was defined by rearrangements in the long arm of chromosome 7 (7q) (in 100% of the cases), cluster 1B (five cases) by deletions in 17p (100%), and cluster 1C (12 cases) by rearrangements in 1q (75%) and deletions of 6q (67%) and 13q (42%). Two cases within cluster 1 did not group with any of the subgroups mentioned above. Cluster 2 was characterized by the presence of trisomy 12 (100%). These four clusters/subgroups were also correlated with cytogenetic complexity (defined as number of chromosomal changes in addition to the IG/BCL3 fusion). Cluster 1A was associated with a medium level of cytogenetic complexity (median/range ¼ 3/1-6), clusters 1B and 1C by a high level of complexity (median/range ¼ 5/3-8 and 7/3-11, respectively) and cluster 2 by low complexity (median/ range ¼ 2/1-4).
Correlation of pathology, IgVH mutation frequency and cluster analysis Figure 2 shows a multivariate display of the association between the cluster analysis, histopathological diagnosis, cytogenetic complexity and IgVH mutation frequency. The different clusters/ subgroups derived from the statistical analysis of chromosomal changes associated with the IG/BCL3 fusion were associated with the histopathological diagnosis and IgVH mutation frequency. In general, clusters 1A-1C were associated with a wide variety of pathologies (with the exception of the three DLBCL, that appeared exclusively in cluster 1C) in which IgVH was mostly mutated (or had a 98-99.5% sequence identity to germline IgVH). The karyotypes from these cases were frequently complex, especially those from cluster 1C. In contrast to cluster 1, the great majority of the cases in cluster 2 was diagnosed as B-CLL/SLL, lacked IgVH mutations and mostly displayed simple karyotypes with trisomy 12 together with the IG/BCL3 fusion. The IgVH mutation frequency in cluster 1 (median/range ¼ 1.5/0-4.1%) was significantly higher than that in cluster 2 (median/range ¼ 0.0/0-0.4%, P ¼ 0.002; Figure 3 ). Chromosomal complexity was also found to be significantly higher in cluster 1 (median/range ¼ 6/1-11) than in cluster 2 (median/range ¼ 2/1-4, Po0.001). The two cases with a t(14;19) lacking secondary changes were diagnosed as B-CLL and unspecified indolent B-cell lymphoma, respectively, and were IgVH unmutated, which is similar to cluster 2, that is predominantly B-CLLs lacking somatic hypermutation and having low chromosomal complexity. A summary of diagnosis, chromosomal changes and IgVH mutation in the different clusters is shown in Table 2 .
Discussion
According to the WHO classification of hematological tumors, the detection of chromosomal changes is essential to establish a proper diagnosis and to predict prognosis in many leukemias and lymphomas. 30 In B-cell malignancies, translocations juxtaposing oncogenes to the regulatory elements of IG loci are thought to play a primary role in their pathogenesis, for example, t(8;14)(q24;q32) (IGH/MYC) in BL, t(11;14)(q13;q32) (IGH/ CCND1) in MCL and t(14;18)(q32;q21) (IGH/BCL2) in FL. However, some IG translocations, like those affecting the MYC locus, can also arise as secondary events in non-BL B-cell malignancies and are associated with a poor prognosis. 31 In contrast to the above-mentioned translocations, the biologic implications of the t(14;19)(q32;q13) fusing the BCL3 gene to IGH, although it is a well-known cytogenetic change first described in 1983 32 and cloned in 1987, 5 are still unclear. It is commonly accepted that the t(14;19)(q32;q13) is associated with B-CLL as most of the cases reported in the literature have been diagnosed as such. However, case reports indicate that BCL3 translocations are present in multiple pathologies, not only B-cell non-Hodgkin lymphomas, but also Hodgkin lymphomas and T-cell lymphomas (fusing BCL3 to TCRAD instead of to IGH). [1] [2] [3] 5, 11, [13] [14] [15] [16] [17] [18] In agreement with these findings, immunohistochemical studies have identified the presence of BCL3 expression in both B-and T-cell lymphomas pointing to a role of BCL3 in B-and T-cell lymphomagenesis. 33, 34 The major aim of the present study was to perform a thorough cytogenetic, FISH, molecular and histopathologic study of B-cell malignancies bearing a t(14;19)(q32;q13) or variant translocations to shed further light on these pathologic associations.
As some of the reported cases with t(14;19)(q32;q13) seem to lack a BCL3 translocation, we developed a FISH assay to demonstrate BCL3 involvement. We identified a total of 56 Bcell lymphomas with BCL3 translocations. In addition to the most frequent IGH involvement, variant rearrangements affecting the IG light-chain loci were detected in 7% of the cases. This frequency is consistent with the 5-10% frequency reported in the literature for light-chain IG translocations in lymphomas. 8 To our knowledge, this is the first time that t(14;19)(q32;q13) variant translocations have been reported. As some IG translocation partners such as MYC and BCL6 are also involved in translocations to non-IG loci, 31, 35 we screened 21 lymphoid malignancies bearing 19q13 breaks without cytogenetic evidence for IG breaks to determine if this also applied to BCL3. Interestingly, we identified one aggressive B-cell lymphoma with a t(9;19)(p13;q13) translocating BCL3 to a region 0.2-1.1 Mb centromeric to PAX5 in 9p13. A t(8;9)(q24;p13) translocation fusing MYC to the same region centromeric to PAX5 has recently been reported. 36, 37 These findings suggest the presence of a region in 9p13 that is able to activate oncogenes like BCL3 or MYC, for example, by a promoter or enhancer exchange mechanism.
We also detected B-cell malignancies with t(14;19)(q32;q13) or variant translocations lacking BCL3 involvement that might indicate either the presence of BCL3-associated alternative breakpoint regions or suggest the presence of additional candidate oncogenes in 19q. Interestingly, RELB, another member of the NF-kB pathway is located 250 Kb telomeric to BCL3 and spanned by the telomeric BACs of our BCL3-specific FISH assay. It could be speculated that alternative breakpoints might target this gene, although this hypothesis seems unlikely, as we did not detect any breakpoint within the telomeric BACs of the BCL3 probe. To our knowledge, there are three additional cloned t(14;19) described in B-cell malignancies. These could be mistaken as IGH/BCL3 fusions at the cytogenetic level, but the underlying change actually fuses IGH to a non-BCL3 locus, that is CEBPA in 19q13.1, 38,39 SPIB in 19q13.3 40 and CCNE1 in 19q12 (Nagel et al. in preperation). In our study, three cases with cytogenetically proven t(14;19)(q32;q13) or variants contained a break in IG, but our FISH assay for BCL3 did not show evidence for a breakpoint. Involvement of CCNE1, CEBPA and SPIB as IG partners in two cases with available material was ruled out by FISH (data not shown).
To study the biologic and pathologic significance of IG/BCL3 fusions, only those cases with FISH-proven IG/BCL3 were included in further examinations. From all 52 cases with FISHproven IG/BCL3 fusion and available chromosome analysis, the t (14;19) or variant appeared at diagnosis in the primary clone in 48 cases and as a secondary change during karyotypic progression in four cases. Two of these later cases were B-CLLs that had þ 12 as primary aberration and acquired t(14;19) in a 41 This association between chromosomes 12 and 19 does not appear in B-cell malignancies other than B-CLLs, in which IG/BCL3 fusions are not associated with trisomy 12 but with other rearrangements and higher chromosomal complexity.
To determine whether there are underlying subgroups of B-cell malignancies with an IG/BCL3 fusion based on the presence of additional chromosomal changes, we performed an unsupervised cluster analysis of the recurrent secondary chromosomal alterations. This analysis detected the presence of two distinct clusters. Cluster 1 mostly included a heterogeneous group of B-cell lymphoproliferative diseases different from B-CLL. This cluster was divided into three subgroups. Cluster 1A was characterized by aberrations in chromosome arm 7q. These 7q aberrations are frequently observed in MZL, 42, 43 and represented 29% of the cases in cluster 1A. Overall, from the nine MZLs of our series, 44% contained 7q aberrations. Cluster 1B was associated with deletions in chromosome arm 17p. This region harbors the tumor suppressor gene TP53 that is a well-known poor prognostic marker in B-cell malignancies. 44, 45 Cluster 1C was characterized by a high number of chromosomal changes frequently including rearrangements in 1q and deletions in 6q and 13q. Cluster 2 comprised the great majority of the cases diagnosed as B-CLL and was characterized by the presence of trisomy 12. Interestingly, among all the IG/BCL3-positive B-CLLs investigated in the present study, 73% bore a cytogenetically detected trisomy 12, which is significantly higher than the 16% reported in the literature for unselected B-CLLs. 46 The histopathological panel review of IG/BCL3-positive B-cell lymphomas was performed in all 25 cases with available material but was biased toward non-B-CLL subtypes. This review revealed that, although the immunophenotype of B-CLL and the cytology of small lymphocyte-like cells is detectable in a subset of cases (primarily in the peripheral blood), the majority of B-cell lymphomas with BCL3 translocations reviewed were not B-CLL but either indolent or aggressive lymphomas with an increased number of blasts. Thus, although our series is biased towards lymphomas with abnormal metaphases, which may be more aggressive than those lacking metaphases, it is tempting to speculate that the BCL3 translocation contributes to an accelerated course of the disease with early transformation of primarily indolent B-NHL. However, the majority of aggressive lymphomas lacked convincing features of a preceding low-grade lymphoma such as coexistent indolent and aggressive lymphomas, and the BCL3 translocation could also be observed in primary aggressive lymphomas such as diffuse large B-cell lymphomas.
Most of the cases diagnosed as B-CLL in our series could not be centrally reviewed. A recent report has suggested that t(14;19)-positive with B-CLL features might represent a different entity, which was named t(14;19)-positive small B-CLL leukemia. 12 Supporting this hypothesis, B-CLLs described herein were frequently reported as being morphologically and/or immunophenotypically atypical. However, the lack of sufficient pathological data in the B-CLLs in our series does not allow to shed further light into this hypothesis and additional studies are required.
The presence or absence of somatic mutations in IgVH genes is a useful marker for studying the cellular origin of B-cell malignancies and is also a marker for prognosis. With regard to B-CLLs, two groups have been identified. B-CLL with unmutated IgVH genes has been shown to be associated with an unfavorable prognosis, whereas B-CLL with mutated IgVH genes tend to have a more favorable clinical outcome. The t(2;14)(p13;q32) translocation involving BCL11A in B-CLL has been recently shown to be predominately associated with the unmutated B-CLL group, 23 but no similar studies have been carried out so far in B-CLLs with a t(14;19) translocation. In this study, we have evaluated the IgVH gene status in 26 B-cell lymphomas (14 B-CLL and 12 other B-cell lymphomas) with FISH-proven IG/BCL3 involvement. Thirteen out of 14 B-CLLs/SLL were shown to bear unmutated IgVH (more than 99.5% sequence identity to germline IgVH) sequences, whereas the IgVH genes in most non-B-CLL/SLL lymphomas had either between 98 and 99.5% sequence identity to germline IgVH or were mutated (o98% sequence identity), that is five (42%) and four (33%), respectively. Remarkably, three B-CLLs from our series (20%) expressed a highly similar B-cell antigen receptor (i.e. V4-39/D6-13/JH5a). Independent studies have also shown this rearrangement to be associated with B-CLLs (with unmutated IgVH). 48, 49 Our findings further support the concept that B-CLL precursors might be selected by a common antigen.
The IGH breakpoints in t(14;19)(q32;q13), as in t(2;14) (p13;q32), 23 mostly involve switch regions suggesting that these translocations happened as a defective class switch recombination, which can take place both in T-cell-dependent immune responses in germinal centers or in T-cell-independent immune responses outside such structures. The observation of frequently unmutated IgVH genes and common antigen receptors in B-CLL with IG/BCL3 fusion suggests that this translocation results from an error in class switching during T-cell-independent immune responses.
The present study provides for the first time a comprehensive analysis of a large series of IG/BCL3-positive B-cell malignances. Our findings suggest the presence of two different groups of B-cell malignances showing a IG/BCL3 juxtaposition, which were difficult to diagnose according to established criteria. One group comprises a rather heterogeneous group of B-cell malignancies, with frequent complex karyotypes and mutated IgVH genes. The other group comprises cases diagnosed as atypical B-CLLs with simple karyotypes, frequently with additional trisomy 12 and unmutated IgVH genes.
